Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 14.8% in December

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 10,900 shares, a drop of 14.8% from the December 15th total of 12,800 shares. Based on an average daily trading volume, of 28,500 shares, the short-interest ratio is presently 0.4 days. Currently, 0.2% of the shares of the stock are short sold.

Aprea Therapeutics Trading Up 2.9 %

Shares of APRE stock opened at $3.85 on Friday. The stock’s 50-day moving average price is $3.35 and its 200-day moving average price is $3.46. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $8.85. The stock has a market capitalization of $20.91 million, a price-to-earnings ratio of -1.37 and a beta of 0.75.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.11. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The business had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.45 million. As a group, research analysts predict that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research report on Wednesday.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is currently owned by institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.